Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,759
Closed -$240K 577
2025
Q4
$240K Sell
1,759
-25
-1% -$3.6K 0.01% 462
2025
Q3
$263K Buy
1,784
+79
+5% +$11K 0.02% 435
2025
Q2
$221K Sell
1,705
-882
-34% -$107K 0.01% 464
2025
Q1
$309K Buy
2,587
+216
+9% +$26.8K 0.02% 342
2024
Q4
$275K Buy
2,371
+93
+4% +$11.8K 0.02% 343
2024
Q3
$308K Buy
2,278
+236
+12% +$31.6K 0.03% 323
2024
Q2
$269K Buy
2,042
+4
+0.2% +$544 0.02% 338
2024
Q1
$263K Buy
2,038
+287
+16% +$34.7K 0.03% 313
2023
Q4
$200K Buy
+1,751
New +$175K 0.02% 334

Other funds holding XYL

Keel Point's XYL Position: Q1 2026 in Review

Keel Point sold out of Xylem (XYL) in Q1 2026, closing a stake of 1,759 shares — an estimated $240K sold.

Keel Point first reported a position in XYL in Q4 2023 and held it in 9 quarters. The position peaked at $309K in Q1 2025. 1,107 funds tracked by Wall St. Rank hold XYL as of Q1 2026.

  • Keel Point reported no remaining Xylem position as of Q1 2026 after selling out during the quarter.
  • Keel Point sold 1,759 Xylem shares in Q1 2026, an estimated $240K.
  • Keel Point first reported a position in Xylem in Q4 2023 and held it in 9 quarters.
  • Keel Point's Xylem position peaked at $309K in Q1 2025.
  • 1,107 funds tracked by Wall St. Rank held Xylem as of Q1 2026.

Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.